科迪塞平通过调节p53/MDM2反循环来改善牛皮样皮肤损伤
Ya Chen1,2, Congcong Zhu1,2, Zongguang Tai1,2
1Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai, 200443, China.
Molecular biotechnology
|June 24, 2024
概括
Kordycepin 是 Cordyceps militaris 的一种化合物,通过调节编程细胞死亡 (细胞亡) 和正常化 p53-MDM2 途径,有效治疗牛皮. 这项研究支持Cordycepin.
科学领域:
- 皮肤病学和药理学
- 细胞生物学和分子机制
背景情况:
- 细胞亡,或编程细胞死亡,对于免疫平衡至关重要;它的功能障碍与牛皮等自身免疫性疾病有关.
- 牛皮涉及受损的角质细胞亡和异常的增殖.
- 来自Cordyceps militaris的cordycepin已知具有细胞亡调节的特性,但其在牛皮的机制尚不清楚.
研究的目的:
- 阐明Cordicepin在治疗牛皮中的药理机制.
- 调查Cordycepin对状细胞增殖和亡途径的影响.
- 为了评估Cordicepin在牛皮的治疗潜力.
主要方法:
- 生物信息学分析以确定潜在的亡途径.
- 在体外实验中使用HaCaT细胞来评估增殖和亡标志物的实验 (PCNA,Ki-67,BAX,BCL-2,p53).
- 在体内研究使用因伊米基莫德 (IMQ) 诱导的牛皮类小鼠模型,接受了Cordycepin凝治疗.
主要成果:
- 科迪塞宾抑制了IL-17A诱导的HaCaT细胞增殖和下调的PCNA和Ki-67.
- 通过调节BAX,BCL-2和p53的表达,科尔迪塞促进了细胞亡.
- 科迪塞宾使p53-MDM2反循环正常化,并改善了小鼠的IMQ诱导的牛皮样皮肤病变.
结论:
- 科尔迪塞宾通过调节p53-MDM2的亡途径,显示出抗牛皮的作用.
- 这些发现支持Cordicepin作为治疗牛皮的活性药物成分 (API) 的潜力.
- 需要进一步的研究来充分探索Cordicepin在皮肤病学中的治疗应用.
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:23Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K